ANG 14 7000 00

PTO/SB/08A (68-43)

Approved for use through 07/31/2006. ONB 0651-0930

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
approvork. Reduction Act of 1995, no persons are required to respond to a collection of information unless its contains as valid OMB

Substitute for form 1449A/PTO INFORMATION DISCLOSURE				Complete if Known		
				Application Number	10/575,998	
				Filing Date	April 17, 2006	
SIAIEMI	STATEMENT BY APPLICANT (use as many sheets as necessary)			First Named Inventor	Kenneth Walter Sinden	
(u				Art Unit		
				Examiner Name		
Sheet	1	of	2	Attorney Docket Number	GJE-7647	

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	U1	US-4,579,855	04-01-1986	Bömches et al.	All		
	U2	US-					
	U3	US-					
	U4	US-					
	U5	US-					
	U6	US-					
	U7	US-					
	U8	US-					
	U9	US-					

	FOREIGN PATENT DOCUMENTS						
		Foreign Patent Document	Publication Date	Publication Date Name of Patentee or	Pages, Columns, Lines,		
Examiner Initials*	No.1	Country Code 3 - Number 4 - Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T*	
	F1						
	F2						
	F3						
	F4						
	F5						
	F6						
	F7						

Examiner	Date
Signature	Considered

EXAMINER: Initial if reference considered, whether or not distain is in conformance with MPEP 600. Draw line through citation if no in conformance and not considered, include copy of his form with next communication to applicant. Applicant's unique clation designation number (optional). *See Kind Codes of conformance and not conformance and not

This collection of information is required by 3T CFR 197 and 198. The information is required to obtain or retain a benefit by the poults which is to file (and by the USPTO by process) an application. Confidentially is gowened by 35 U.S.C. 122 and 3T CFR 1-14. This collection is estimated to lake 2 bours to complete, including aghiering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the inforvidual case. Any comments on the amount of the you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Grizer. U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA. 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA. 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Sheet

Cor	nplete if Known	
Application Number	10/575,998	
Filing Date	April 17, 2006	
First Named Inventor	Kenneth Walter Sinden	
Group Art Unit		
Examiner Name		
Attorney Docket Number	GJE-7647	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), dale, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	R1	CARROLL, F.I. and BLACKWELL, J.T. "Optical Isomers of Aryl-2-piperidylmethanol Antimalarial Agents. Preparation, Optical Purity, and Absolute Stereochemistry" Journal of Medicinal Chemistry, 1974, p. 210-219, Vol. 17, No. 2.		
	R2	KARLE, J.M. and KARLE, I.L. "Crystal Structure of (-)-Mefloquine Hydrochloride Reveals Consistency of Configuration with Biological Activity" Antimicrobial Agents and Chemotherapy, May 2002, p. 1529-1534, Vol. 48, No. 5.		
	R3	KISS, A. et al. "Solid State Investigation of Mefloquine Hydrochloride" Journal of Pharmaceutical & Biomedical Analysis, 1994, p. 889-893, Vol. 12, No. 7.		
	R4	KITAMURA, S. et al. "Polymorphism of Melloquine Hydrochloride" International Journal of Pharmaceutics, 1994, p. 127-144, Vol. 101.		
	R5			
	R6			
	R7			
	R8			
	R9			
	R10			
	R11			
	R12			
	R13			

Examiner Signature	/D Margaret Seaman/	Date Considered	06/25/2009
*EXAMINER: Initial i	f reference considered, whether or not citation is in conformance with MPEP	609. Draw line th	ough citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including

gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S.
Trademark Office, P.O. 80x 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.